TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous electrical acupoint stimulation for cisplatin- chemotherapy induced nausea and vomiting.

Chemotherapy-induced nausea and vomiting significantly impacts the quality of life for 70%-80% of cancer patients receiving chemotherapy. The P6 acupressure point is traditionally used to relieve these symptoms and has shown benefits in pain relief and other conditions. If studies on Transcutaneous electrical acupoint stimulation yield positive results, it could be integrated as an effective method to manage chemotherapy-induced nausea and vomiting, enhancing patient comfort and treatment outcomes while potentially reducing the need for dosage adjustments. This study aims to address gaps in current treatments, improving management and quality of life for affected cancer patients.

Inclusion Criteria:

• Male and female patients who their ages between 40 and 60.
• All patients diagnosed with cancer and planned to receive TACE treatment with cisplatin (60 mg) as the main drug. The chemotherapy regimen will not include steroids.
• Karnofsky's score ≥60.
• All patients will receive the same antiemetic drug.
• None of them receiving other physical therapy modalities to treat nausea and vomiting.
• The skin of acupoint site receiving electrical acupoint stimulation must be intact and without visible evidence of injury
• All patient can tolerate mild discomfort following electrical stimulation.
• All patients enrolled in the study will have their informed consent.

Exclusion Criteria:

• Combined use of other venous chemotherapy within 5 days after Transarterial Chemoembolization
• Other confounding factors that may cause nausea and vomiting (such as intestinal obstruction, anorexia, and so on)
• Having vomited or used 5 HT3 receptor antagonists or other antiemetics within 24 hours before Transarterial Chemoembolization .
• Receiving concurrent radiotherapy
• Severe uncontrolled complications and unstable metastases
• Installing pacemaker, Pregnancy.
• History of convulsions or seizure disorder.
• Cognitive dysfunction, unable to finish Scale
• Transcutaneous electrical acupoint stimulation treatment within the past year regardless of indication.